None listed
Conditions
Interventions
ASM981 Type of group
The ASM 981 will be provided to patients in 50 or 100 g tubes, and will be used b.i.d. according to need, while the signs and symptoms of AD are present.
Sponsors
NOVARTIS BIOSCIENSES PERU S.A.,
Eligibility
Inclusion criteria
Inclusion criteria: Men or women Age> 3 months The subjects must have a clear diagnosis of atopic dermatitis. History of mild to moderate atopic dermatitis.
Exclusion criteria
Exclusion criteria: That they are pregnant or breastfeeding. That they have pregnancy potential and are not using a reliable and medically accepted method of contraception, during the study and until at least 4 weeks after the end of the treatment phase.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Quality of Life Index Measure:Parents Quality of Life Index - Atopic Dermatitis Timepoints:12 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:They will consist of the monitoring and the registration of all the EAs and of all the EASs following the same guidelines of the original protocol. Measure:Security assessments Timepoints:12 month | — |
Countries
Arabia Saudi, Austria, Botswana, Brazil, Colombia, Czech Republic, Finland, Germany, Guatemala, Iceland, Israel, Kuwait, Latovia, Mexico, New Zealand, Peru, Portugal, Spain, United Kindgdom, United States, Venezuela
Outcome results
None listed